The aging brain and its disorders

  • A. Carlsson
Part of the Key Topics in Brain Research book series (KEYTOPICS)


In the search for the meachanisms underlying the aging process and for approaches to alleviate the resulting functional losses, the neurotransmitter strategy appears to offer great promise. This strategy is based on the hypothesis that the biological properties and vulnerabilities of nerve cells depend largely on the types of neurotransmitters they produce or are exposed to by innervation from other nerve cells. It permits an insight into the complex interactions and imbalances between neuronal systems that lead to age related functional losses. The aging process may not only cause transmitter deficiencies. Owing to failure of regulatory mechanisms neurotransmitters may prove harmful to the cells producing them as well as to cells exposed to them by innervation. The former mechanism is illustrated by the toxic potential of catecholamine autoxidation, the latter by excitotoxins.


Dopaminergic Neuron Aging Brain Locus Ceruleus Mesencephalic Reticular Formation Choline Acetyl Transferase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alexander GE, DeLong MR, Strick PL (1986) Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Ann Rev Neurosci 9: 357–381PubMedCrossRefGoogle Scholar
  2. Björklund A, Lindvall O (1986) Catecholaminergic brain stem regulatory systems. In: Field J (ed) Handbook of physiol — The nervous system IV. Am Physiol Soc Washington DC, pp 155–235Google Scholar
  3. Carlsson A (1978) Antipsychotic drugs, neurotransmitters and schizophrenia. Am J Psychiatry 135 (2): 164–173Google Scholar
  4. Carlsson A (1981) Aging and brain neurotransmitters. In: Platt D (ed) Funktionsstörungen des Gehirns im Alter. Schattauer, Stuttgart New York, S 67–82Google Scholar
  5. Carlsson A ( 1988 a) Brain neurotransmitters in aging and dementia: recent findings. In: Barchas JD, Bunney WE (eds) Perspectives in psychopharmacology: a collection of papers in honor of Earl Usdin. Alan R Liss, New York, pp 209–223Google Scholar
  6. Carlsson A (1988 b) The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1:179–186PubMedCrossRefGoogle Scholar
  7. Carlsson A (1989) Neurotransmission and the aging brain: new vistas. In: Carlsson A, Kanowski S, Allain H, Spiegel R (eds) Cerebral insufficiency. Trends in research and treatment. Parthenon Publishing Group Ltd, Caster-ton Hall Carnforth, pp 1–15Google Scholar
  8. Carlsson M, Carlsson A (1989 a) The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J Neural Transm 75: 221–226PubMedCrossRefGoogle Scholar
  9. Carlsson M, Carlsson A (1989 b) Dramatic synergism between MK-801 and clonidine with respect to locomotor stimulatory effect in monoamine-depleted mice. J Neural Transm 77: 65–71PubMedCrossRefGoogle Scholar
  10. Carlsson M, Svensson A (1990) Interfering with glutamatergic neurotransmission by means of MK-801 administration discloses the locomotor stimulatory potential of other transmitter systems in rats and mice. Pharmacol Biochem Behav 36 (in press)Google Scholar
  11. Elam M (1985) On the physiological regulation of brain norepinephrine neurons in rat locus ceruleus. Thesis, University of Göteborg, SwedenGoogle Scholar
  12. Fornstedt B, Carlsson A (1989) A marked rise in 5-S-cysteinyl-dopamine levels in guinea pig striatum following reserpine treatment. J Neural Transm 77: 155–161CrossRefGoogle Scholar
  13. Fornstedt B, Rosengren E, Carlsson A (1986) Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species. Neuropharmacology 25: 451–454PubMedCrossRefGoogle Scholar
  14. Fornstedt B, Brun A, Rosengren E, Carlsson A (1989) The apparent autoxidation rate of catechols in dopamine-rich regions of human brains increases with the degree of depigmentation of substàntia nigra. J Neural Transm (PD-Sect) 1: 279–295CrossRefGoogle Scholar
  15. Goldman-Rakic PS, Selemon LD (1986) Topography of corticostriatal projections in nonhuman primates and implications for functional parcellation of the neostriatum. In: Jones EG, Peters A (eds) Cerebral cortex, vol 5. Plenum Publishing Corporation, New York, pp 447–466Google Scholar
  16. Heimer L, Alheid GF, Zaborszky L (1985) Basal ganglia. In: Paxinos G (ed) The rat nervous system, vol 1. Forebrain and midbrain. Academic Press, New York, pp 37–86Google Scholar
  17. Moldéus P, Nordenskjöld M, Bolesfoldi G, Eiche A, Haglund U, Lambert B (1983) Genetic toxicity of dopamine. Mutat Res 124: 9–24PubMedCrossRefGoogle Scholar
  18. Nauta WJF (1989) Reciprocal links of the corpus striatum with the cerebral cortex and limbic system: a common substrate for movement and thought. In: Mueller J (ed) Neurology and psychiatry: a meeting of minds. Karger, Basel München Paris, pp 43–63Google Scholar
  19. Nyth A-L, Balldin J, Elgen K, Gottfries C-G (1987) Behandlung med citalopram vid demens. Normalisering av DST (with summary in English). Nord Psykiat Tidskr 41: 423–430CrossRefGoogle Scholar
  20. Nyth A-L, Gottfries C-G, Elgen K, Engedahl K, Harenko A, Karlsson I, Koskinen T, Larsson L, Nygaard H, Samuelsson SM, Yli-Kertula A (1988) The effect of citalopram in dementia disorders. A Scandinavian multicenter study. Poster, CINP Congress Munich, August 15–19, 1988Google Scholar
  21. Penney JB Jr, Young AB (1983) Speculations on the functional anatomy of basal ganglia disorders. Ann Rev Neurosci 6: 73–94PubMedCrossRefGoogle Scholar
  22. Penney JB Jr, Young AB (1986) Striatal inhomogeneities and basal ganglia function. Movement Disordes 1: 3–15CrossRefGoogle Scholar
  23. Raffa RB, Ortegón ME, Robisch DM, Martin GE (1989) In vivo demonstration of the enhancement of MK-801 by L-glutamate. Life Sci 44: 1593–1599PubMedCrossRefGoogle Scholar
  24. Schmidt WJ, Bury D (1988) Behavioural effects of N-methyl-D-aspartate in the anterodorsal striatum of the rat. Life Sci 43: 545–549PubMedCrossRefGoogle Scholar
  25. Selemon LD, Goldman-Rakic PS (1985) Longitudinal topography and interdigitation of corticostriatal projections in the Rhesus monkey. J Neurosci 5: 776–794PubMedGoogle Scholar
  26. Svanborg A, Berg S, Mellström D, Nilsson L, Persson G (1986) Possibilities of preserving physical and mental fitness and autonomy in old age. In: Häfner H, Moschel G, Sartorius N (eds) Mental health in the elderly. Springer, Berlin Heidelberg New York, pp 195–202CrossRefGoogle Scholar
  27. Tedroff J, Aquilonius S-M, Hartvig P, Lundqvist H, Gee AG, Uhlin J, Längström B (1988) Monoamine re-uptake sites in the human brain evaluated in vivo by means of 11C-nomifensine and positron emission tomography: the effects of age and Parkinson’s disease. Acta Med Scand 77: 192–201Google Scholar

Copyright information

© Springer-Verlag Wien 1990

Authors and Affiliations

  • A. Carlsson
    • 1
  1. 1.Department of PharmacologyUniversity of GöteborgGöteborgSweden

Personalised recommendations